Revolution Medicines, INC Form 4 insider transactions
NASDAQ
Flavia Borellini, a director at Revolution Medicines, filed an amended Form 4 to correct previously reported amounts for restricted stock units and stock options granted on June 20, 2024.
NASDAQ
Barbara Weber, a director at Revolution Medicines, files an amended Form 4 to correct previously reported amounts for restricted stock units and stock options granted on June 20, 2024.
NASDAQ
Lorence H. Kim, a director at Revolution Medicines, filed an amended Form 4 to correct previously reported amounts for restricted stock units (RSUs) and stock option awards granted on June 20, 2024.
NASDAQ
Alexis Borisy, a director at Revolution Medicines, filed an amended SEC Form 4 to correct previously reported amounts for restricted stock units (RSUs) and stock options granted on June 20, 2024.
NASDAQ
Sushil Patel, a director at Revolution Medicines, filed an amended SEC Form 4 to correct previously reported amounts for restricted stock units and stock options granted on June 20, 2024.
NASDAQ
Sandra Horning, a director at Revolution Medicines, filed an amended Form 4 to correct previously reported amounts for restricted stock units and stock options granted on June 20, 2024.
NASDAQ
Jeff Cislini, General Counsel of Revolution Medicines, sold 2,000 shares of common stock at an average price of $38.4698 on June 26, 2024, under a pre-arranged 10b5-1 trading plan.
NASDAQ
Form 4: Revolution Medicines Executive Stephen Michael Kelsey Reports Stock Option Exercises and Sales
Stephen Michael Kelsey, a key executive at Revolution Medicines, executed stock option exercises and subsequent sales of common stock under a pre-arranged 10b5-1 trading plan.
NASDAQ
Director Sandra Horning reports acquisition of Revolution Medicines stock and options.
NASDAQ
Director Sushil Patel acquired 4,800 shares of common stock and 16,700 stock options in Revolution Medicines, Inc.
NASDAQ
Form 4: Revolution Medicines Director, Alexis Borisy, Reports Acquisition of Shares and Stock Options
Director Alexis Borisy reports acquiring 4,800 shares of common stock and 16,700 stock options in Revolution Medicines, Inc.
NASDAQ
Form 4: Revolution Medicines Director Lorence H. Kim Reports Acquisition of Shares and Stock Options
Director Lorence H. Kim reports acquisition of 4,800 shares of common stock and 16,700 stock options in Revolution Medicines, Inc.
NASDAQ
Director Barbara Weber reports acquiring 4,800 shares of common stock and stock options for 16,700 shares in Revolution Medicines.
NASDAQ
Form 4: Revolution Medicines Director Flavia Borellini Reports Acquisition of Shares and Stock Options
Director Flavia Borellini reports acquisition of 4,800 shares of common stock and 16,700 stock options in Revolution Medicines, Inc.
NASDAQ
Form 4: Revolution Medicines Director Elizabeth Anderson Reports Acquisition of Shares and Stock Options
Director Elizabeth Anderson reports acquiring shares and stock options in Revolution Medicines, Inc.
NASDAQ
Mark A. Goldsmith, CEO of Revolution Medicines, sold 11,950 shares of common stock on June 17, 2024, to satisfy tax withholding obligations related to vesting restricted stock units.
NASDAQ
Jack Anders, CFO of Revolution Medicines, sold 1,893 shares of common stock on June 17, 2024, to cover tax obligations related to vesting restricted stock units.
NASDAQ
Margaret Horn, Chief Operating Officer of Revolution Medicines, sold 4,415 shares of common stock on June 17, 2024, to satisfy tax withholding obligations related to vesting restricted stock units.
NASDAQ
Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, sold 3,349 shares of common stock on June 17, 2024, to cover tax obligations related to vesting restricted stock units.
NASDAQ
Jeff Cislini, General Counsel of Revolution Medicines, sold 1,757 shares of common stock on June 17, 2024, to cover tax obligations related to vesting restricted stock units.
NASDAQ
Wei Lin, Chief Medical Officer of Revolution Medicines, sold 5,589 shares of common stock on June 17, 2024, to cover withholding taxes related to the vesting of restricted stock units.
NASDAQ
Form 4: Revolution Medicines CEO Mark Goldsmith Executes Stock Option and Sells Shares Under 10b5-1 Plan
Revolution Medicines CEO Mark Goldsmith exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan, while also transferring shares into a family trust.
NASDAQ
Jeff Cislini, General Counsel of Revolution Medicines, sold a total of 1,500 shares of common stock on May 21, 2024, under a pre-arranged 10b5-1 trading plan.
NASDAQ
Revolution Medicines' CFO, Jack Anders, exercised stock options and sold shares on May 3, 2024, under a pre-arranged 10b5-1 trading plan.
NASDAQ
Revolution Medicines CEO Mark Goldsmith sold shares of common stock on April 10, 2024, under a pre-arranged 10b5-1 trading plan.
NASDAQ
Form 4: Revolution Medicines Director Sushil Patel Executes Stock Option and Sells Shares Under 10b5-1 Plan
Director Sushil Patel of Revolution Medicines exercised stock options and sold shares on April 10, 2024, under a pre-arranged 10b5-1 trading plan.
NASDAQ
Jeff Cislini, General Counsel of Revolution Medicines, sold a total of 1,500 shares of common stock on March 27, 2024, under a pre-arranged 10b5-1 trading plan.
NASDAQ
Jeff Cislini, General Counsel of Revolution Medicines, sold 1,252 shares of common stock on March 18, 2024, to cover tax obligations related to vesting restricted stock units.
NASDAQ
Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, sold 2,123 shares of common stock on March 18, 2024, to cover tax obligations related to vesting restricted stock units.
NASDAQ
Margaret Horn, Chief Operating Officer of Revolution Medicines, sold 2,914 shares of common stock on March 18, 2024, to cover tax withholding obligations upon the vesting of Restricted Stock Units (RSUs).